Allied Market Research: Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market to Reach $9.5 Billion, Globally, by 2020

Jul 09, 2015, 08:24 ET from Allied Market Research

PORTLAND, Oregon, July 9, 2015 /PRNewswire/ --

According to a new report by Allied Market Research, titled, "World Castration-Resistant Prostate Cancer (CRPC) Therapeutics - Market Opportunity and Forecast, 2014-2020", the global CRPC therapeutics market would generate a revenue of $9.5 billion by 2020, registering a CAGR of 9.1% from 2015 to 2020. Hormonal therapy segment spearheads among all the therapy types, governing around 4/5th of the global market value in 2014 and would sustain its market position throughout 2020.

     (Logo: http://photos.prnewswire.com/prnh/20140911/647229 )

The global CPRC therapeutics market has witnessed high growth in the past few years and would continue to grow at a consistent pace due to the high unmet clinical need associated with the disease. Large amount of drugs in pipeline, augmented patient awareness and untapped nmCRPC space would largely drive the market growth during the forecast period. On the other hand, introduction of novel treatments would be difficult as long as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require an improvement in overall survival period. Moreover, lack of differentiation in mechanism of action among the approved and novel agents along with factors such as premium pricing and uncertain reimbursement policies would hinder the market growth during the analysis period.

To view the report, visit the website at https://www.alliedmarketresearch.com/castration-resistant-prostate-cancer-therapeutics-market

The market would gain traction in the emerging countries of Asia-Pacific and third-world countries such as Africa and Latin America. Asia Pacific and LAMEA region would collectively constitute around 1/3rd of the overall market by 2020. The large undiagnosed patient population, rapid urbanization, rising disposable income, improved government funding towards healthcare and growing awareness about prostate cancer would be the prime reasons responsible for the impressive market growth in these regions. The market growth would mainly rely on the novel breakthrough treatments with improved overall survival benefits. The survival benefit would be instrumental in governing the peak sales and market penetration of novel approved drugs.

Key findings of the study: 

  • North America CRPC market spearheads the regional CRPC markets and would continue to lead throughout the forecast period
  • Radiotherapy segment is projected to grow at a CAGR of 24.5% throughout the forecast period, fastest among all CRPC therapy segments
  • Immunotherapy segment is expected to grow more than threefold over the forecast period
  • Asia Pacific CRPC market is expected to garner 1/5th of the overall market revenue by 2020
  • European market is expected to expand more than two-fold as compared to North American market (within hormonal therapy segment) over the forecast period    
  • Countries like India and China holds immense future market potential as there is a higher count of undiagnosed CRPC patients.

The principal and key strategy adopted by the leading players in the market is product launch. In order to implement the strategy, acquisitions and partnerships/collaborations have been the key strategies adopted by the leading industry players. The key companies profiled in the report are Astellas Inc., Johnson & Johnson, Sanofi S.A, Dendreon Corporation, Bayer AG, and others.

Similar market studies by Allied Market Research -

Cancer Therapeutics and Biotherapeutic Market - Cancer is one of the leading causes of death worldwide.  According to the World Health Organization, about 8.2 million deaths occurred in 2012 due to cancer.  The most common kinds of cancer which tend to result in death are lung cancer, liver cancer, stomach cancer, colorectal cancer, breast cancer and oesophageal cancer. Apart from the mature chemotherapy market, biotherapy has emerged as a new approach for cancer treatment. Biotherapy boosts the body's immune system to slow or stop the growth of cancer cells. Growing demand for personalized medicine and the introduction of novel approaches are expected to drive the market growth. Astra Zeneca PLC, Biogen IDEC, Bristol-Myers Squibb, Sanofi, Merck, Johnson & Johnson, Schering-Plough and Roche are some players in this market.

View the Cancer Therapeutics and Biotherapeutic Market Report at https://www.alliedmarketresearch.com/cancer-therapeutics-biotherapeutic-market

Oncology/Cancer Drugs Market - Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option for treating various cancer types, especially for blood cancer (leukemia). Rising incidence of various cancer conditions, growing popularity of advance therapies (biological and targeted drug therapies), patents expiration of leading drugs along with commercialization of biosimilars are the few factors driving the growth of global oncology drugs market. However, high cost involved in new drug development coupled with threat of failure and adverse effects associated with cancer drugs therapies would restrain the growth of the market. Commercialization of advanced therapeutics such as targeted and immunotherapies would reduce the negative influence of restraints and fuel the market growth.

View the Oncology/Cancer Drugs Market Report at https://www.alliedmarketresearch.com/oncology-cancer-drugs-market

Lung Cancer Therapeutics Market - Lung cancer is a malignant lung carcinoma that is characterized by abnormal cell growth in lung tissue. As the tumor grows in size, it decreases the lungs' ability to provide oxygen to bloodstream. The primary lung carcinomas originate from epithelial cells and classified as non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). Major symptoms of lung cancer include coughing, body mucus, wheezing, shortness of breath, chest pain and weight loss. Lung cancer has high mortality rate all over the globe and the foremost reason includes cigarette smoking. Treatments of lung cancer include chemotherapy and radiation therapy. This report provides in-depth discussion on global lung cancer therapeutics market and includes past and current trends with future forecast up to 2020. The report provides threats and opportunities for new and existing companies running the business in this market. The report is informative towards geographical segmentation and identifies profitable areas.

View the Lung Cancer Therapeutics Market Report at https://www.alliedmarketresearch.com/lung-cancer-therapeutics-market

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions". AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Int'l: +1 (503) 505-6949
Toll Free: + 1-800-792-5285 (U.S. & Canada)
E-mail: sales@alliedmarketresearch.com


SOURCE Allied Market Research